Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats Effect of intestinal enhancer on acyclovir absorption

Drug Development and Industrial Pharmacy

Volumn 35, Issue 9, 2009, Pages 1082-1091

  Merzlikine, Alexei ^a   Rotter, Charles ^a   Rago, Brian ^a   Poe, Julie ^a   Christoffersen, Curt ^a   Thomas, V Hayden ^a   Troutman, Matthew ^a   El Kattan, Ayman ^a  

^a PFIZER INC   (United States)

Author keywords

Acyclovir; Carbomer 974P; Chitosan glutamate; EDTA; Paracellular; Renal recovery

Indexed keywords

ACICLOVIR; CARBOPOL 974P; CHITOSAN GLUTAMATE; EDETATE SODIUM; GLUTAMIC ACID DERIVATIVE; MANNITOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOLAYER CULTURE; NONHUMAN; RAT; TIGHT JUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ACRYLATES; ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EDETIC ACID; ELECTRIC IMPEDANCE; EXCIPIENTS; GLUTAMATES; HUMANS; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70350668795     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040902774156     Document Type: Article

References (30)

1. Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. (2007). Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol, 3:469-489
2. Thomas VH, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N, et al. (2006). The road map to oral bioavailability: An industrial perspective. Expert Opin Drug Metab Toxicol, 2:591-608.
3. Avdeef A. (2001). Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem, 1:277-351.
4. Avdeef A, Testa B. (2002). Physicochemical profiling in drug research: A brief survey of the state-of-the-art of experimental techniques. Cell Mol Life Sci, 59:1681-1689
5. He YL, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, et al. (1998). Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci, 87:626-633
6. Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci, 89:429-442
7. Junginger HE, Verhoef JC. (1998). Macromolecules as safe penetration enhancers for hydrophilic drugs-a fiction? Pharm Sci Technol Today, 1:370-376
8. Sogias IA, Williams AC, Khutoryanskiy VV. (2008). Why is chitosan mucoadhesive? Biomacromolecules, 9:1837-1842
9. Borchard G, Luessen HL, de Boer AG, Verhoef JC, Lehr C-M, Junginger HE. (1996). The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release, 39:131-138
10. Kotze AF, Luessen HL, de Leeuw BJ, de Boer AG, Verhoef JC, Junginger HE. (1998). Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release, 51:35-46.
11. Arai K, Kinumaki T, Fujita T. (1968). Toxicity of chitosan. Bull Tokai Reg Fish Res Lab, 43:89-94.
12. Grabovac V, Guggi D, Bernkop-Schnurch A. (2005). Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev, 57:1713-1723
13. Lehr CM, Bouwstra JA, Kok W, De Boer AG, Tukker JJ, Verhoef JC, et al. (1992). Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J Pharm Pharmacol, 44:402-407
14. Lu Z., Chen W, Hamman JH, Ni J, Zhai X. (2008). Chitosanpolycarbophil interpolyelectrolyte complex as an excipient for bioadhesive matrix systems to control macromolecular drug delivery. Pharm Dev Technol, 13:37-47.
15. Bernkop-Schnurch A. (1998). The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release, 52:1-16.
16. Bernkop-Schnurch A, Pasta M. (1998). Intestinal peptide and protein delivery: Novel bioadhesive drug-carrier matrix shielding from enzymatic attack. J Pharm Sci, 87:430-434
17. Chiou WL, Ma C, Chung SM, Wu TC, Jeong HY. (2000). Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int J Clin Pharmacol Ther, 38:532-539
18. Ganapathy ME, Huang W, Wang H, Ganapathy V, Leibach, FH. (1998). Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun, 246:470-475
19. Burnette TC, de Miranda P. (1994). Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos, 22:60-64
20. Kim SH, Choi YM, Lee MG. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm, 21:1-17.
21. Gibaldi M, Perrier D. (1992). Pharmacokinetics. New York: Marcel Dekker, Inc.;1982.
22. Miller JC, Miller JN. (1992). Statics for analytical chemistry. West Sussex, England: Ellis Hardwood Limited.
23. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res, 10:1093-1095
24. De Miranda P, Krasny HC, Page DA, Elion GB. (1981). The disposition of acyclovir in different species. J Pharmacol Exp Ther, 219:309-315
25. Meadows KC, Dressman JB. (1990). Mechanism of acyclovir uptake in rat jejunum. Pharm Res, 7:299-303.
26. Shao Z, Park GB, Krishnamoorthy R, Mitra AK. (1994). The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2 prime;-ester prodrugs. Pharm Res, 11:237-242
27. Zornoza T, Cano-Cebrian MJ, Nalda-Molina R, Guerri C, Granero L, Polache A. (2004). Assessment and modulation of acamprosate intestinal absorption: Comparative studies using in situ, in vitro (CACO-2 cell monolayers) and in vivo models. Eur J Pharm Sci, 22:347-356
28. Luessen HL, Rentel CO, Kotze AF, Lehr C-M, de Boer AG, Verhoef JC, et al. (1997). Mucoadhesive polymers in peroral peptide delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal membrane in vitro. J Control Release, 45:15-23.
29. Sheskey PJ, Rowe RC, Owen SC, eds. (2005). Handbook of pharmaceutical excipients. Washington DC: American Association of Pharmaceutical Sciences.
30. Kofoid CA, McNeil E, Cailleau R. (1932). Electrometric pH determinations of the walls and contents of the gastrointestinal tracts of normal albino rats. Univ Calif Publ Zool, 36:347-355